OSE — Ose Immunotherapeutics SA Share News
0.000.00%
Last trade - 00:00- €44.94m
- €57.66m
- €2.69m
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO
Brief: OSE Immunotherapeutics Says Board Decides Not To Appeal Court Decision
Brief: OSE Immunotherapeutics Provides Updates On Ongoing Court Proceedings
Brief: OSE Immunotherapeutics Appoints Thomas Gidoin As Chief Financial Officer
Brief: Ose Immunotherapeutics Announces Positive Clinical Progress For Late-Stage Proprietary Cancer Vaccine
Brief: OSE, Boehringer Ingelheim To Develop Treatments For Cancer And CRM Diseases
Brief: Ose Immunotherapeutics’ Global License To Develop OSE-230 Becomes Effective
Brief: OSE Immunotherapeutics Receives EUR 8.4 Mln In Public Funding For Lung Cancer Vaccine Candidate
Brief: Ose Immunotherapeutics Announces Peer-Reviewed Publication On Novel Myeloid Immune Checkpoint Clec-1
Brief: Ose Immunotherapeutics Posts FY Operating Loss Of 23.0 Million Euros
Brief: OSE Immunotherapeutics Provides 2024 Outlook
Brief: Ose Immunotherapeutic: Positive Interim Data Analysis From Study Of FR104/VEL-101 Immunotherapy In Renal Transplant
Brief: OSE Immunotherapeutics Partners With GenDx To Develop Companion Diagnostic For Cancer Vaccine
Brief: OSE Immunotherapeutics Announces First Clinical Results For BI 770371
Brief: Ose Immunotherapeutics Announces First Clinical Results For BI 770371
Brief: Ose Immunotherapeutics Presents First Positive Clinical Results With Its anti-PD1 OSE-279 In Advanced Solid Tumors